PortalPublikationenUpdate Breast Cancer 2021 Part 5 - Advanced Breast Cancer

Update Breast Cancer 2021 Part 5 - Advanced Breast Cancer

Standard

Update Breast Cancer 2021 Part 5 - Advanced Breast Cancer. / Lüftner, Diana; Schütz, Florian; Stickeler, Elmar; Fasching, Peter A; Janni, Wolfgang; Kolberg-Liedtke, Cornelia; Kolberg, Hans-Christian; Thomssen, Christoph; Müller, Volkmar; Fehm, Tanja N; Belleville, Erik; Bader, Simon; Untch, Michael; Welslau, Manfred; Thill, Marc; Tesch, Hans; Ditsch, Nina; Lux, Michael P; Wöckel, Achim; Aktas, Bahriye; Schneeweiss, Andreas; Würstlein, Rachel; Hartkopf, Andreas D.

in: GEBURTSH FRAUENHEILK, Jahrgang 82, Nr. 2, 02.2022, S. 215-225.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung

Harvard

Lüftner, D, Schütz, F, Stickeler, E, Fasching, PA, Janni, W, Kolberg-Liedtke, C, Kolberg, H-C, Thomssen, C, Müller, V, Fehm, TN, Belleville, E, Bader, S, Untch, M, Welslau, M, Thill, M, Tesch, H, Ditsch, N, Lux, MP, Wöckel, A, Aktas, B, Schneeweiss, A, Würstlein, R & Hartkopf, AD 2022, 'Update Breast Cancer 2021 Part 5 - Advanced Breast Cancer', GEBURTSH FRAUENHEILK, Jg. 82, Nr. 2, S. 215-225. https://doi.org/10.1055/a-1724-9569

APA

Lüftner, D., Schütz, F., Stickeler, E., Fasching, P. A., Janni, W., Kolberg-Liedtke, C., Kolberg, H-C., Thomssen, C., Müller, V., Fehm, T. N., Belleville, E., Bader, S., Untch, M., Welslau, M., Thill, M., Tesch, H., Ditsch, N., Lux, M. P., Wöckel, A., ... Hartkopf, A. D. (2022). Update Breast Cancer 2021 Part 5 - Advanced Breast Cancer. GEBURTSH FRAUENHEILK, 82(2), 215-225. https://doi.org/10.1055/a-1724-9569

Vancouver

Lüftner D, Schütz F, Stickeler E, Fasching PA, Janni W, Kolberg-Liedtke C et al. Update Breast Cancer 2021 Part 5 - Advanced Breast Cancer. GEBURTSH FRAUENHEILK. 2022 Feb;82(2):215-225. https://doi.org/10.1055/a-1724-9569

Bibtex

@article{8ddf69a353e7417c8e17090b872f51c6,
title = "Update Breast Cancer 2021 Part 5 - Advanced Breast Cancer",
abstract = "Despite the COVID 19 pandemic and mostly virtual congresses, innovation in the treatment of breast cancer patients continues at an unabated pace. This review summarises the current developments. Initial overall survival data for CDK4/6 inhibitor treatment in combination with an aromatase inhibitor as the first advanced line of therapy in treatment-naive postmenopausal patients have been published. Similarly, a trial comparing trastuzumab-deruxtecan versus trastuzumab-emtansine revealed a clear benefit regarding progression-free survival. Understanding of biomarkers making checkpoint inhibitor therapy particularly effective is increasing, and new compounds such as oral selective estrogen receptor destabilisers (SERDs) are entering clinical development and completing the first phase III trials.",
author = "Diana L{\"u}ftner and Florian Sch{\"u}tz and Elmar Stickeler and Fasching, {Peter A} and Wolfgang Janni and Cornelia Kolberg-Liedtke and Hans-Christian Kolberg and Christoph Thomssen and Volkmar M{\"u}ller and Fehm, {Tanja N} and Erik Belleville and Simon Bader and Michael Untch and Manfred Welslau and Marc Thill and Hans Tesch and Nina Ditsch and Lux, {Michael P} and Achim W{\"o}ckel and Bahriye Aktas and Andreas Schneeweiss and Rachel W{\"u}rstlein and Hartkopf, {Andreas D}",
note = "The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ).",
year = "2022",
month = feb,
doi = "10.1055/a-1724-9569",
language = "English",
volume = "82",
pages = "215--225",
journal = "GEBURTSH FRAUENHEILK",
issn = "0016-5751",
publisher = "Georg Thieme Verlag KG",
number = "2",

}

RIS

TY - JOUR

T1 - Update Breast Cancer 2021 Part 5 - Advanced Breast Cancer

AU - Lüftner, Diana

AU - Schütz, Florian

AU - Stickeler, Elmar

AU - Fasching, Peter A

AU - Janni, Wolfgang

AU - Kolberg-Liedtke, Cornelia

AU - Kolberg, Hans-Christian

AU - Thomssen, Christoph

AU - Müller, Volkmar

AU - Fehm, Tanja N

AU - Belleville, Erik

AU - Bader, Simon

AU - Untch, Michael

AU - Welslau, Manfred

AU - Thill, Marc

AU - Tesch, Hans

AU - Ditsch, Nina

AU - Lux, Michael P

AU - Wöckel, Achim

AU - Aktas, Bahriye

AU - Schneeweiss, Andreas

AU - Würstlein, Rachel

AU - Hartkopf, Andreas D

N1 - The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ).

PY - 2022/2

Y1 - 2022/2

N2 - Despite the COVID 19 pandemic and mostly virtual congresses, innovation in the treatment of breast cancer patients continues at an unabated pace. This review summarises the current developments. Initial overall survival data for CDK4/6 inhibitor treatment in combination with an aromatase inhibitor as the first advanced line of therapy in treatment-naive postmenopausal patients have been published. Similarly, a trial comparing trastuzumab-deruxtecan versus trastuzumab-emtansine revealed a clear benefit regarding progression-free survival. Understanding of biomarkers making checkpoint inhibitor therapy particularly effective is increasing, and new compounds such as oral selective estrogen receptor destabilisers (SERDs) are entering clinical development and completing the first phase III trials.

AB - Despite the COVID 19 pandemic and mostly virtual congresses, innovation in the treatment of breast cancer patients continues at an unabated pace. This review summarises the current developments. Initial overall survival data for CDK4/6 inhibitor treatment in combination with an aromatase inhibitor as the first advanced line of therapy in treatment-naive postmenopausal patients have been published. Similarly, a trial comparing trastuzumab-deruxtecan versus trastuzumab-emtansine revealed a clear benefit regarding progression-free survival. Understanding of biomarkers making checkpoint inhibitor therapy particularly effective is increasing, and new compounds such as oral selective estrogen receptor destabilisers (SERDs) are entering clinical development and completing the first phase III trials.

U2 - 10.1055/a-1724-9569

DO - 10.1055/a-1724-9569

M3 - SCORING: Review article

C2 - 35169389

VL - 82

SP - 215

EP - 225

JO - GEBURTSH FRAUENHEILK

JF - GEBURTSH FRAUENHEILK

SN - 0016-5751

IS - 2

ER -